BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24360663)

  • 1. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
    Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
    Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
    Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
    BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
    Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
    Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
    Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
    Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
    Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
    Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lin CH; Lee H; Cheng YW
    Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
    Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
    Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
    Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
    Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
    Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
    Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
    Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y
    Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
    Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
    Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
    Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
    BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer.
    Bao BY; Lin VC; Huang SH; Pao JB; Chang TY; Lu TL; Lan YH; Chen LM; Ting WC; Yang WH; Hsieh CJ; Huang SP
    Ann Surg Oncol; 2010 Jun; 17(6):1675-81. PubMed ID: 20204532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.